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ABSTRACT
Eighty isolates of Shigella spp. (37 Shigella ﬂexneri
and 43 Shigella sonnei) from patients with travel-
lers’ diarrhoea were studied. Susceptibility tests
revealed high levels of resistance, especially to
ampicillin (65%), tetracycline (78%) and trimeth-
oprim (75%), and particularly among the
S. ﬂexneri isolates. Dihydrofolate reductase 1
genes (dfrA1) were prevalent among the trimeth-
oprim-resistant isolates, while oxa genes predom-
inated among the ampicillin-resistant isolates.
Chloramphenicol resistance was associated with
production of chloramphenicol acetyltransferase,
while nalidixic acid-resistant isolates had a single
mutation in the gyrA gene. The results indicate a
continuing need for resistance surveillance and
rational use of antimicrobial agents.
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The increase in intercontinental travel to exotic
destinations has resulted in infection by Shigella
spp. becoming an important cause of travellers’
diarrhoea (TD). Although the incidence of TD
caused by Shigella spp. is much lower than that of
TD caused by the main aetiological agent (i.e.,
enterotoxigenic Escherichia coli), Shigella causes a
more severe disease with greater morbidity. Fur-
thermore, Shigella spp. have been progressively
acquiring resistance to most of the antibiotics used
for the treatment of infections, partly because of
their ability to acquire resistance genes located on
plasmids or transposons [1]. However, other socio-
economic and behavioural factors have also con-
tributed to this increase in resistance [2]. Increased
international travel means that the appearance of
multiresistant pathogenic strains anywhere in the
world can rapidly become a public health problem
in other countries. Thus, the treatment decision for
shigellosis in developed countries is now com-
monly inﬂuenced by the patient’s travel history
[3]. The present report describes the susceptibility
patterns and mechanisms of resistance in Shigella
spp. with various geographical origins, isolated
from patients with TD.
Shigella isolates were obtained between 1995
and 2000 from the stool samples of patients
presenting with TD at the Hospital Clinic, Barce-
lona, Spain. Isolates were identiﬁed to the genus
and species level by conventional biochemical
methods [4] and agglutination with speciﬁc
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antisera (Sanoﬁ Diagnostic Pasteur, Marnes-La
Coquette, France). MICs of ampicillin (AMP),
tetracycline (TET), chloramphenicol (CHL), trim-
ethoprim (TMP), nalidixic acid (NAL) and
ciproﬂoxacin (CIP) were determined using Etest
strips (AB BioDisk, So¨lna, Sweden), following the
manufacturer’s recommendations. The presence
of b-lactamases was studied by isoelectric focus-
ing and speciﬁc PCRs for the TEM-, CARB-, SHV-
and OXA-type genes as described previously
[5,6]. Chloramphenicol acetyltransferase activity
was determined as described elsewhere [6].
Dihydrofolate reductase genes (dfr) were detected
by use of a PCR–restriction fragment length
polymorphism method described previously [7].
PCR ampliﬁcation and sequencing of the quino-
lone resistance-determining regions of gyrA and
parC were performed using the primers and
conditions described elsewhere [8,9].
In total, 37 Shigella ﬂexneri and 43 Shigella sonnei
with various geographical origins, shown previ-
ously to be epidemiologically unrelated [10], were
included in the study. A high percentage of
multiresistance was observed among these strains
(Table 1). The highest rates of resistance were
seen for tetracycline (78%), trimethoprim (76%)
and ampicillin (65%), which is in accordance with
previous reports of isolates from low-income
countries [6,11]. Differences in susceptibility
levels were observed between S. ﬂexneri and
S. sonnei, with S. ﬂexneri generally being more
resistant, except to trimethoprim. Interestingly,
not only was the TETR TMPR AMPR CHLR NALS
phenotype the most prevalent phenotype
among S. ﬂexneri isolates (37.8%), it was only
observed in this species, mainly because all
S. sonnei isolates were susceptible to chloram-
phenicol. S. sonneimostly presented a TETR TMPR
AMPR CHLS NALS (30%) or a TETR TMPR AMPs
CHLS NALS (30%) phenotype. The mechanisms
of resistance underlying the AMPR and TMPR
phenotypes are shown in Table 2. Brieﬂy, ampi-
cillin resistance was usually related to the pres-
ence of a b-lactamase gene, mainly encoding OXA
type enzymes. Genes for OXA-1 were abundant,
particularly among S. ﬂexneri strains; S. sonnei
mainly harboured genes encoding OXA-2 and
OXA-5. This apparent species speciﬁcity for
certain genes could suggest their carriage on
plasmids belonging to incompatibility group R.
TEM-encoding genes were second in abundance;
CARB- and SHV-encoding genes were rare, but
were also found occasionally. Previous studies
have shown that OXA-type enzymes constitute
Table 1. Resistance proﬁles of Shigella spp. isolated from patients with travellers’ diarrhoea
Area
Tetracycline Chloramphenicol Ampicillin Trimethoprim
S. ﬂexneri S. sonnei Total (%) S. ﬂexneri S. sonnei Total (%) S. ﬂexneri S. sonnei Total (%) S. ﬂexneri S. sonnei Total (%)
West Africa 12 ⁄ 13 5 ⁄ 6 17 ⁄ 19 (89.5) 6 ⁄ 13 0 ⁄ 6 6 ⁄ 19 (31.5) 7 ⁄ 13 3 ⁄ 6 10 ⁄ 19 (53) 6 ⁄ 13 6 ⁄ 6 12 ⁄ 19 (63)
East Africa 2 ⁄ 2 1 ⁄ 2 3 ⁄ 4 (75) 2 ⁄ 2 0 ⁄ 2 2 ⁄ 4 (50) 2 ⁄ 2 2 ⁄ 2 4 ⁄ 4 (100) 2 ⁄ 2 1 ⁄ 2 3 ⁄ 4 (75)
South Africa 1 ⁄ 1 – 1 ⁄ 1 (100) 1 ⁄ 1 – 1 ⁄ 1 (100) 1 ⁄ 1 – 1 ⁄ 1 (100) 1 ⁄ 1 – 1 ⁄ 1 (100)
North Africa 1 ⁄ 3 3 ⁄ 7 4 ⁄ 10 (40) 0 ⁄ 3 0 ⁄ 7 0 ⁄ 10 (0) 1 ⁄ 3 3 ⁄ 7 4 ⁄ 10 (40) 2 ⁄ 3 5 ⁄ 7 7 ⁄ 10 (70)
Central America ⁄
Caribbean
6 ⁄ 8 10 ⁄ 14 16 ⁄ 22 (73) 4 ⁄ 8 0 ⁄ 14 4 ⁄ 22 (18) 7 ⁄ 8 10 ⁄ 14 17 ⁄ 22 (77) 5 ⁄ 8 11 ⁄ 14 16 ⁄ 22 (73)
South America 5 ⁄ 6 – 5 ⁄ 6 (83) 4 ⁄ 6 – 4 ⁄ 6 (66) 5 ⁄ 6 – 5 ⁄ 6 (83) 5 ⁄ 6 – 5 ⁄ 6 (83)
Southeast Asia 1 ⁄ 1 – 1 ⁄ 1 (100) 1 ⁄ 1 – 1 ⁄ 1 (100) 1 ⁄ 1 – 1 ⁄ 1 (100) 1 ⁄ 1 – 1 ⁄ 1 (100)
Middle East – 2 ⁄ 3 2 ⁄ 3 (66) – 0 ⁄ 3 0 ⁄ 3 (0) – 1 ⁄ 3 1 ⁄ 3 (33.33) – 2 ⁄ 3 2 ⁄ 3 (66)
India ⁄Nepal 1 ⁄ 1 8 ⁄ 9 9 ⁄ 10 (90) 1 ⁄ 1 0 ⁄ 9 1 ⁄ 10 (10) 1 ⁄ 1 4 ⁄ 9 5 ⁄ 10 (50) 1 ⁄ 1 8 ⁄ 9 9 ⁄ 10 (90)
Undetermined 2 ⁄ 2 2 ⁄ 2 4 ⁄ 4 (100) 1 ⁄ 2 0 ⁄ 2 1 ⁄ 4 (25) 2 ⁄ 2 2 ⁄ 2 4 ⁄ 4 (100) 2 ⁄ 2 2 ⁄ 2 4 ⁄ 4 (100)
Total 31 ⁄ 37 31 ⁄ 43 20 ⁄ 37 0 ⁄ 43 27 ⁄ 37 25 ⁄ 43 25 ⁄ 37 35 ⁄ 43
Percentage 84 72 54 0 73 58 65 81
Table 2. Distribution of b-lactamases and dfr genes among
resistant isolates of Shigella spp
Resistance mechanism S. sonnei S. ﬂexneri
b-lactamase genes
(S. sonnei, n = 25; S. ﬂexneri, n = 27)
TEM type (pI c. 5.2) 7 (28%) 9 (33.3%)
SHV type (pI c. 7.6) 0 1 (3.7%)
OXA 1 ⁄ 2 type
(OXA-1, -4, -30, -31)
1 (4%) 20 (74%)
OXA 2 ⁄ 3 type
(OXA-2, -3, -15, -21, -32, -34)
10 (40%) 0
OXA 5 ⁄ 7 type (OXA-5, -7, -10, -11, -13,
-14, -16, -17, -19, -28)
19 (76%) 3 (11%)
CARB type (pI c. 5.6) 2 (8%) 0
Undetermined 1 (4%) 0
Dihydrofolate reductase genes
(S. sonnei, n = 35; S. ﬂexneri, n = 25)
dfrA1 27 (75%) 13 (52%)
dfrA14 14 (39%) 6 (24%)
dfrA5 0 1
dfrA15 1 (2,7%) 0
dfrA12 0 1
dfrA7 0 1
Undetermined 4 (11%) 6 (24%)
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the most prevalent resistance mechanism for
ampicillin in S. ﬂexneri, while S. sonnei usually
harbours TEM-type b-lactamases [12–14].
Trimethoprim resistance was correlated with
the presence of dfr genes, with dfrA1 being the
most prevalent type, in agreement with previous
ﬁndings [15]. However, a signiﬁcant number of
isolates harboured a dfrA14 gene, encoding a
DHFR-Ib enzyme, which has biochemical proper-
ties similar to those of DHFR-I, to which it is
thought to be related. To our knowledge, this is
the ﬁrst report of dfrA14 in Shigella spp., although
this gene has been shown previously to be quite
common in other Enterobacteriaceae [16,17].
Other, less common, types of dfr gene were also
detected (dfrA5, dfrA15, dfrA12 and dfrA7), all as
cassettes within type I integrons (unpublished
data).
All chloramphenicol-resistant isolates were
shown to have chloramphenicol acetyltransf-
erase activity; however, while 56% of the
S. ﬂexneri isolates were chloramphenicol-resistant,
all of the S. sonnei isolates were susceptible. This
difference has been reported previously [6,11].
Furthermore, retrospective studies of the resist-
ance trends of Shigella spp. from a speciﬁc site
have shown a very important decrease over
time in the levels of resistance to chloramphenicol
in S. sonnei, while they might even have increased
for S. ﬂexneri [18].
Only three isolates were resistant to nalidixic
acid (MICs 64–128 mg ⁄L) but susceptible to
ciproﬂoxacin (MIC < 1 mg ⁄L). Of these, two
were S. sonnei isolates from India, a country
known for extensive use of ﬂuroquinolones,
while the third was a S. ﬂexneri isolate from
Mali. All three isolates had a mutation in the
gyrA gene (Ser83 to Leu in the S. ﬂexneri and
one of the S. sonnei isolates; Asp87 to Tyr in the
second S. sonnei isolate). Both of these mutations
have been described previously in Shigella spp.
[19–21]. No mutations were found in parC,
which explains the susceptibility of these iso-
lates to ciproﬂoxacin.
Although differences were observed in the
resistance to certain antibiotics for isolates from
different geographical areas, ﬁrm conclusions
cannot be reached on the basis of the relatively
small number of isolates investigated. However, it
would be expected that the antibiotic consump-
tion trends of each region would inﬂuence the
resistance proﬁles of the isolates.
The treatment of shigellosis has a long history
of failures. The levels of resistance to the
current ﬁrst-line treatments in developing coun-
tries are not encouraging. Nalidixic acid has
become the ﬁrst-line treatment for children from
endemic developing areas, despite its toxicity,
and chloramphenicol continues to be used in
many African rural areas (D. Schellenberg,
personal communication). Other alternatives,
such as cephalosporins, are appropriate for the
treatment of TD, but their relatively high price
and lack of availability rule them out for use in
endemic countries. Thus, the need for other less
expensive options is a pressing issue. Moreover,
the rising number of travellers to developing
countries is resulting in the potential spread of
multiresistant microorganisms. Therefore, this is
a worldwide problem, with signiﬁcant public
health implications, that justiﬁes constant sur-
veillance of antimicrobial resistance in bacteria
causing TD.
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